Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each Monotherapy
Status:
Recruiting
Trial end date:
2023-01-12
Target enrollment:
Participant gender:
Summary
Study to assess the anti-hypertensive efficacy and safety of the extemporaneous combination
of Nebivolol 5 mg in combination with Amlodipine 5 mg or AML 10 mg in lowering the sitting
diastolic BP after 8 weeks of treatment inpatients with uncontrolled BP previously treated
with Nebivolol (NEB) or Amlodipine (5 mg) monotherapies for at least 4 weeks.